Price Controls put US Biopharma at Risk

Vital Transformation’s Grumpy Old Men discuss their recently published research which found that 60% of FDA approved medicines from 2011- 2020 originated in the United States. Their study, “The US Ecosystem for Medicines - How new drug innovations get to patients”, shows a profound shift in global innovation and highlights the success of U.S. biopharma in creating new medicines.

Duane Schulthess, CEO of Vital Transformation, joins Dr Joseph Hammang, VT’s US Business Director, and Dr Harry Bowen, VT’s consulting economist in a discussion about the U.S. drug development ecosystem and its unique ability to adapt to the market demands of both orphan indications and potential blockbuster therapies to help patients with unmet medical needs.
 
VT’s Grumpy Old Men also highlight the many unintended consequences of the legislative proposals being made in Washington, DC to control the price of drugs, and the slippery slope that Europe is already traveling down due to similar policies.
 
Sources Quoted in this Podcast:

https://bit.ly/3S8G8KW

https://bit.ly/3lF0U8O

https://bit.ly/3KcWqQM

https://www.the-scientist.com/infographics/cell-and-gene-therapy-tracker-64450

See omnystudio.com/listener for privacy information.